Assignment&lt;footref rid="foot01"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/footref&gt; of human PLCB2 encoding PLC β2 to human chromosome 15q15 by fluorescence in situ hybridization

Park, S.H.; Ryu, Soo Hyung; Suh, Pann Ghill; Kim, H.

doi:10.1159/000015166

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fe showed a weak correlation with Mg, K, P, and S and was linked to other minerals through S, sharing negative correlations with the expression of Phospholipase C Beta 2 gene (PLCB2). The protein coded by this gene is critical to Ca efflux 24 , although no correlation with Ca amount was found in our data, nor in our previously reported DEGs 9 . The relationship of PLCB2 gene expression with Fe and S is undocumented, although Fe was reported to cleave the Phospholipase C Beta 2 protein in the cornea of bovine, porcine and humans 25 .…”

Section: Discussioncontrasting

confidence: 94%

Genetic regulators of mineral amount in Nelore cattle muscle predicted by a new co-expression and regulatory impact factor approach

Afonso

Fortes

Reverter

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Mineral contents in bovine muscle can affect meat quality, growth, health, and reproductive traits. to better understand the genetic basis of this phenotype in nelore (Bos indicus) cattle, we analysed genome-wide mRNA and miRNA expression data from 114 muscle samples. The analysis implemented a new application for two complementary algorithms: the partial correlation and information theory (pcit) and the regulatory impact factor (Rif), in which we included the estimated genomic breeding values (GeBVs) for the phenotypes additionally to the expression levels, originally proposed for these methods. We used PCIT to determine putative regulatory relationships based on significant associations between gene expression and GeBVs for each mineral amount. then, Rif was adopted to determine the regulatory impact of genes and miRnAs expression over the GeBVs for the mineral amounts. We also investigated over-represented pathways, as well as pieces of evidences from previous studies carried in the same population and in the literature, to determine regulatory genes for the mineral amounts. for example, NOX1 expression level was positively correlated to Zinc and has been described as Zinc-regulated in humans. Based on our approach, we were able to identify genes, miRnAs and pathways not yet described as underlying mineral amount. the results support the hypothesis that extracellular matrix interactions are the core regulator of mineral amount in muscle cells. putative regulators described here add information to this hypothesis, expanding the knowledge on molecular relationships between gene expression and minerals. Besides nutritional quality, mineral amount affects meat quality in many ways. For example, the tenderization process of the skeletal muscle is driven by the action of the calcium-dependent protease calpain 1-4. Minerals also affect reproduction, as copper, zinc, selenium and manganese supplementation improves pregnancy rate 5 ; as well as health and growth performance 6,7 in beef cattle. Mineral homeostasis regulation partially depends on genetic factors, among others 8. Thus, understanding the genetic aspects linked to mineral amount in bovine muscle can

show abstract

Section: Discussioncontrasting

confidence: 94%

Genetic regulators of mineral amount in Nelore cattle muscle predicted by a new co-expression and regulatory impact factor approach

Afonso

Fortes

Reverter

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Based on the products obtained on amplification of the radiation hybrids, the human PLC-b2 gene was mapped to chromosome 15, confirming previous reports (Lyu et al, 1996;Park et al, 1998).…”

Section: Resultssupporting

confidence: 85%

Evidence for two alternatively spliced forms of phospholipase C‐β2 in haematopoietic cells

2000

View full text Add to dashboard Cite

Summary. Alternatively spliced forms have been reported for several phospholipase C (PLC) isozymes, but not for PLC-b2, the most abundant PLC-b in platelets. PLC-b2 cDNA cloned from the HL-60-cell cDNA library is 3543 bases long, coding for 1181 amino acids. Compared with the published sequence, a deletion of 45 nucleotides (2755±2799 nt, amino acids 864±878) was detected in platelet and leucocyte mRNA amplified by reverse transcription (RT) polymerase chain reaction (PCR) using primers corresponding to 1814±1838 nt (forward) and 3328±3352 nt (reverse). Amplification of genomic DNA using primers corresponding to 2575±2596 nt and 2864±2885 nt yielded a , 750 bp product; restriction analysis and sequencing revealed the 45-bp exon flanked by introns of 198 bp and 118 bp. Amplification of leucocyte and platelet cDNA using the same primers yielded products of , 310 nt and , 265 nt, with (PLC-b2a) and without (PLCb2b) the 45-nt sequence. Thus, two alternatively spliced forms (1181 and 1166 amino acids) of PLC-b2 are generated in haematopoietic cells. They differ in the carboxyl terminal sequence implicated in interaction of PLC-b enzymes with Gaq, particulate association and nuclear localization. We propose that the PLC-b2 splice variants may be regulated differentially with distinct roles in signal transduction.

show abstract

Recent Developments and Future Directions in the Treatment of Multiple Myeloma

Pichardo

Singhal

Mehta

et al. 2003

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Multiple Myeloma (MM) is a B cell neoplasia affecting approximately 14,400 new individuals in the United States each year. Although MM remains an incurable disease, encouraging advances have been made in its therapy in the recent past. High dose chemotherapy with autologous stem cell transplantation has been shown in randomized controlled trials to improve survival in MM and is currently considered the first line treatment for all patients except those with advanced age of co-morbidities. For such patients, conventional chemotherapy with melphalan and steroids continue to be the treatment of choice. The use of tandem stem cell transplants and the use of both myeloablative and nonmyeloablative allogeneic stem cell transplantation remains investigational. Thalidomide is a new therapeutic option with promising results; however, it is associated with significant side effects including deep venous thrombosis and peripheral neuropathy. Its use in combination with other chemotherapy agents is still under investigation. Novel promising agents are currently under clinical trials including Proteosome Inhibitors and much more potent thalidomide analogs or immunomodulators. This review summarizes recent developments in the therapy and supportive care of MM and introduces the newer drugs in preclinical and early clinical trials.

show abstract

Assignment<footref rid="foot01"><sup>1</sup></footref> of human PLCB2 encoding PLC β2 to human chromosome 15q15 by fluorescence in situ hybridization

Cited by 4 publications

References 8 publications

Genetic regulators of mineral amount in Nelore cattle muscle predicted by a new co-expression and regulatory impact factor approach

Genetic regulators of mineral amount in Nelore cattle muscle predicted by a new co-expression and regulatory impact factor approach

Evidence for two alternatively spliced forms of phospholipase C‐β2 in haematopoietic cells

Recent Developments and Future Directions in the Treatment of Multiple Myeloma

Contact Info

Product

Resources

About